NASDAQ · GLSI
Healthcare · Biotechnology
$15.63
Down-$0.46 (-2.86%)
Updated Sep 17, 2026, 11:44 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
GLSI closed at $15.63 after 20 trading sessions, down 9.86% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $16.09 | $16.37 | $15.3468 | $15.63 | 121.66K |
| Sep 15, 2026 | $15.81 | $16.43 | $15.35 | $16.09 | 96.84K |
| Sep 14, 2026 | $15.15 | $16.30 | $15.15 | $16.05 | 100.23K |
| Sep 11, 2026 | $15.33 | $15.595 | $15.09 | $15.45 | 75K |
| Sep 10, 2026 | $14.54 | $15.345 | $14.46 | $15.06 | 68.52K |
| Sep 9, 2026 | $15.79 | $16.34 | $14.90 | $15.03 | 103.34K |
| Sep 8, 2026 | $15.71 | $16.25 | $15.53 | $15.90 | 63.06K |
| Sep 4, 2026 | $15.45 | $15.98 | $15.45 | $15.95 | 65.12K |
| Sep 3, 2026 | $15.80 | $16.02 | $15.50 | $15.63 | 46.67K |
| Sep 2, 2026 | $15.01 | $16.02 | $14.9901 | $15.74 | 104.02K |
| Sep 1, 2026 | $14.56 | $15.08 | $14.40 | $15.01 | 98.7K |
| Aug 31, 2026 | $15.50 | $15.6243 | $14.32 | $14.95 | 169.64K |
| Aug 28, 2026 | $18.77 | $18.94 | $14.25 | $15.67 | 372.24K |
| Aug 27, 2026 | $18.04 | $18.89 | $18.0101 | $18.73 | 64.25K |
| Aug 26, 2026 | $18.60 | $18.61 | $17.82 | $18.23 | 61.61K |
| Aug 25, 2026 | $17.46 | $19.64 | $17.44 | $18.59 | 199.13K |
| Aug 24, 2026 | $16.64 | $17.68 | $15.78 | $17.58 | 93.55K |
| Aug 21, 2026 | $16.16 | $17.48 | $15.5401 | $16.67 | 176.79K |
| Aug 20, 2026 | $17.41 | $17.68 | $15.00 | $15.31 | 181.62K |
| Aug 19, 2026 | $17.70 | $18.17 | $17.17 | $17.34 | 112.13K |
The latest Smart Investors Daily articles mentioning GLSI.
GLSI research
Company profile and research snapshot.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 21, 2026 | HC Wainwright & Co. | Buy | — |
| Dec 30, 2025 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2025 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Finnhub · Apr 30, 2026
STAFFORD, Texas, April 30, 2026 -- Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track...
Benzinga · Mar 19, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an
Benzinga · Mar 18, 2026
Benzinga · Mar 17, 2026
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLSI.
